<DOC>
	<DOCNO>NCT00260520</DOCNO>
	<brief_summary>The objective trial determine whether prophylactic low-molecular weight heparin therapy pregnant woman heterozygous Factor V Leiden G20210A prothrombin gene mutation thrombophilia history severe preeclampsia and/or severe fetal growth restriction reduces risk composite outcome preeclampsia , fetal growth restriction , .</brief_summary>
	<brief_title>LMWH Prevent Preeclampsia Fetal Growth Restriction</brief_title>
	<detailed_description>The objective trial determine whether prophylactic low-molecular weight heparin therapy pregnant woman heterozygous Factor V Leiden G20210A prothrombin gene mutation thrombophilia history severe preeclampsia and/or severe fetal growth restriction reduces risk composite outcome preeclampsia , fetal growth restriction , . We also assess effect treatment indicator maternal neonatal complication , growth fetal body composition term fat lean body mass .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Fetal Growth Retardation</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Previous severe preeclampsia Previous severe fetal growth restriction Heterozygous Factor V Leiden Heterozygous G20210A prothrombin gene mutation renal disease chronic hypertension preexist diabetes mellitus homozygosity Factor V Leiden homozygosity prothrombin G20210A mutation hyperhomocysteinemia protein C deficency protein S deficency antithrombin deficiency positive anticardiolipin antibody positive lupus anticoagulant</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>Low molecular weight heparin</keyword>
	<keyword>Preeclampsia</keyword>
	<keyword>Fetal Growth Restriction</keyword>
	<keyword>Thrombophilia</keyword>
	<keyword>Factor V Leiden</keyword>
	<keyword>G20210A prothrombin gene mutation</keyword>
</DOC>